Marketing Asset Templates for MedTech Launch

What This Template Pack Includes

A complete pack of marketing asset templates structured for medical device launch, with regulatory-compliance scaffolding pre-built:

• HCP product brochure (8-page Word + Adobe InDesign templates)
• Patient-facing brochure (4-page Word + Adobe InDesign templates)
• Sales rep detail aid (10-page slide template)
• Master pitch deck (20-slide PowerPoint template)
• Web product page wireframe (HCP and public variants)
• Evidence summary (4-page template with citation framework)
• Trade journal advertisement (full-page and half-page layouts)
• Trade show booth content (banner, handout, and demo script)

Each template includes:

• Regulatory placeholder blocks (MFDS notification number, indication scope, contraindication statement, IFU reference, KLH information)
• Comment annotations explaining what content can go where, and what cannot
• Compliance checklist on the back page or final slide
• Cross-reference points to source labeling/IFU for claim consistency

Why Template-Driven Marketing

Medical device marketing assets are unusual in that the regulatory constraints shape the structure as much as the marketing creativity does. A free-form marketing asset created without regulatory scaffolding typically requires significant rework after legal/regulatory review.

Template-driven asset production reverses the workflow:

1. Marketing team starts with a compliant structural template.
2. Brand voice, visual design, and claims are populated within the template constraints.
3. Regulatory review verifies content within the existing structure (faster than reviewing free-form layouts).
4. Translations replicate the structure across languages, preserving the compliance scaffolding.

Manufacturers running template-driven workflows report 40–60% reduction in regulatory review cycle time on marketing assets.

HCP Product Brochure Structure

The 8-page HCP brochure follows a regulatory-compliant flow:

Page	Content
Cover	Product name, single-claim positioning, product image, manufacturer/KLH attribution
2	Clinical context (what condition, what unmet need, current standard-of-care limitations)
3	Product overview (high-level description, intended use statement, indication summary)
4	Mechanism of action / how it works (technical without being inaccessible)
5	Clinical evidence summary (key trial results, with citation footnotes)
6	Implementation profile (workflow integration, training requirements, technical specs)
7	Safety profile (contraindications, warnings, precautions per IFU)
8	Back cover (contact information, KMDIA approval number when applicable, IFU reference, ISO 13485 / KGMP statement)

The structure is built so the regulatory-required content (indication, contraindications, IFU reference) is always present and always findable. Marketing creativity operates within this structure rather than redesigning around it each time.

Patient-Facing Brochure Differences

The 4-page patient brochure is structurally simpler but has stricter compliance constraints:

• Cover: simple, education-focused (not promotional in tone)
• Page 2: "About this condition" — patient-friendly explanation of the condition
• Page 3: "About this treatment / device" — balanced explanation including limitations
• Back cover: Talk to your doctor language, manufacturer/KLH contact, IFU reference

The patient brochure does not include performance claims, comparative statements, or direct-to-patient promotional language. The structure is education-first by design.

Sales Rep Detail Aid

The detail aid is a sales conversation tool, not a leave-behind. Structure:

• Slide 1: Opening hook — clinical context relevant to this physician/practice
• Slides 2-3: Product positioning vs current state
• Slides 4-5: Clinical evidence (key trial data presented visually)
• Slide 6: Implementation conversation (workflow, training, support)
• Slide 7: Health economics summary (cost vs current state, with disclaimer)
• Slide 8: Reference customer story or case example
• Slide 9: Q&A prompts (objection handling cues)
• Slide 10: Next steps (clinical pilot, demo arrangement, follow-up)

The detail aid is typically presented over 8–15 minutes in a clinical setting. Each slide supports a specific conversational beat.

Master Pitch Deck Structure

The pitch deck is the deeper presentation for purchasing committees, IDN review boards, and academic medical center evaluations. Structure:

• Slides 1–3: Company introduction (who Leanabl is, regulatory credentials, market presence)
• Slides 4–7: Clinical context (the condition, the unmet need, the patient burden, the standard of care)
• Slides 8–12: Product overview (description, intended use, mechanism, key features, technical specs)
• Slides 13–17: Clinical evidence (trial design, outcomes, comparisons to standard of care, post-market data if available)
• Slide 18: Implementation and training
• Slide 19: Health economics
• Slide 20: Summary and next steps

For Korean purchasing committee presentations, the deck typically expands to 25–30 slides with additional Korean-specific content (KFDA approval citation, KLH coverage, Korean reimbursement status, Korean reference customers).

Web Product Page Wireframe

The web product page is structured in two variants:

HCP variant (/products/{name}/hcp or login-gated):

• Hero with product image and single-claim positioning
• Clinical context section
• Product overview with intended use statement
• Mechanism and features
• Clinical evidence (with downloadable citations)
• Implementation and support
• Technical specifications
• Contact / sales inquiry form
• IFU and regulatory information footer

Public variant (/products/{name}):

• Hero with image and education-first headline
• "What this is" section (plain language)
• "What this treats" section
• "How it works" section (high-level, accessible)
• "Talk to your doctor" CTA
• Safety information section (visible, not hidden)
• About the manufacturer / KLH footer
• IFU access link

The variants share visual design but differ in tone, claim density, and CTA targeting.

Evidence Summary

The 4-page evidence summary is a citation-anchored document supporting the marketing materials. Structure:

• Page 1: Headline outcomes (top 3-5 clinical outcomes from trials, with source citations)
• Page 2: Trial details (design, population, methodology) for top 1-2 trials
• Page 3: Comparative or supporting evidence (literature comparisons, real-world evidence)
• Page 4: Citation bibliography (full citations for all referenced studies)

The evidence summary is the document that anchors claims. Marketing materials reference it; regulatory review verifies the marketing materials against it; sales reps cite from it.

Compliance Checklist

Each template includes a compliance checklist as the final page or slide. A condensed version:

• Indication statement consistent with labeled indication
• All claims supported by cited evidence
• Comparative claims reviewed for regulatory compliance per region
• Performance numbers traceable to source studies
• Contraindications referenced
• IFU reference included
• Manufacturer and KLH (where applicable) clearly identified
• Regulatory clearance citation present (FDA 510(k) number, CE mark, MFDS notification number)
• KMDIA approval obtained for Korean assets
• Source language version regulatory-approved before translation
• All translations reviewed for claim consistency with source

Korean-Specific Adjustments

For Korean marketing assets, the templates include Korean-specific overlays:

• KMDIA approval number block (typically bottom of cover or specific compliance footer)
• Korean indication phrasing (often differs subtly from English)
• KLH name and contact (replaces or augments manufacturer contact)
• Comparative claim restriction (Korean templates prompt for absolute claims rather than relative)
• Clinical imagery restrictions (Korean templates note where stock imagery is not acceptable)

Download

Download the Marketing Asset Templates Pack — includes Word, PowerPoint, and Adobe InDesign source files plus a comprehensive style guide.

Where Leanabl Plugs In

The Marketing Assets service handles full marketing asset development with regulatory compliance built in — for teams that prefer to outsource the asset production rather than self-produce from templates. For Korean-specific marketing readiness as part of launch, Korea Full Market Authorization integrates marketing readiness with the regulatory program. For ongoing labeling and IFU alignment that anchors marketing claims, the Labeling and Lean IFU practices keep the canonical content current.